Can I Take Vitamin B12 With Intrarosa (Prasterone)?

The Short Answer on Interaction Risk

Vitamin B12 and Intrarosa do not interact directly. Prasterone is a vaginally delivered form of dehydroepiandrosterone (DHEA) that acts locally in vaginal tissue, converting to estrogen and testosterone within epithelial cells rather than producing the large systemic hormone surges associated with oral or transdermal hormone therapy. Because local conversion keeps serum DHEA changes modest, and because B12 is a water-soluble vitamin processed through entirely separate metabolic pathways, no pharmacokinetic conflict exists between the two.

Where the picture gets more layered is for women who take metformin, a drug that depletes B12 by impairing its absorption in the ileum. Many women using Intrarosa for genitourinary syndrome of menopause (GSM) also have PCOS, metabolic syndrome, or type 2 diabetes and may be on metformin. That combination, not the Intrarosa-B12 pair itself, is the real clinical story.

What Is Intrarosa and Why Do Women Use It?

Intrarosa is the brand name for prasterone 6.5 mg vaginal inserts. The FDA approved Intrarosa in November 2016 specifically for moderate-to-severe dyspareunia (pain during sex) caused by GSM in postmenopausal women.

How Prasterone Works Locally

Unlike oral DHEA supplements, Intrarosa delivers prasterone directly into vaginal epithelial cells. Intracellular enzymes convert it into small amounts of estradiol and testosterone within the tissue itself. This local intracrinology restores vaginal epithelial thickness, increases lubrication, and lowers vaginal pH without producing meaningful increases in systemic estrogen levels, a property that has made it attractive to women who prefer to avoid systemic hormones.

The REJOICE trial, the key phase 3 study, enrolled 325 postmenopausal women and showed that nightly prasterone 6.5 mg significantly improved vaginal cell maturation index, vaginal pH, dyspareunia severity, and vaginal dryness scores versus placebo over 12 weeks. Serum estradiol and testosterone remained within postmenopausal reference ranges throughout.

Which Women Are Using Intrarosa?

Most users are postmenopausal women aged 50-65, but Intrarosa is also used off-label by younger women with premature ovarian insufficiency (POI) and by breast cancer survivors whose oncologists prefer a non-systemic option. The Menopause Society 2023 position statement recognizes vaginal DHEA as an effective option for GSM, particularly when systemic therapy is not appropriate.

What Is Vitamin B12 and Who Needs More of It?

Vitamin B12 (cobalamin) is an essential water-soluble vitamin required for DNA synthesis, red blood cell formation, and myelin maintenance in the nervous system. The NIH Office of Dietary Supplements sets the recommended dietary allowance for adult women at 2.4 mcg/day, rising to 2.6 mcg/day during pregnancy and 2.8 mcg/day during lactation.

Deficiency causes megaloblastic anemia and, critically, peripheral neuropathy that may be irreversible if not caught early. The groups most at risk include:

• Women over 50 (gastric acid declines, reducing absorption of food-bound B12)
• Women following vegan or vegetarian diets
• Women with autoimmune gastritis or confirmed pernicious anemia
• Anyone taking metformin long-term
• Women who have had bariatric surgery

Supplement doses sold over the counter range from 25 mcg to 5,000 mcg. The body absorbs only about 1-2% of doses above 1,000 mcg passively, so high-dose oral B12 is generally well tolerated even without a formal upper intake limit.

The Real Interaction Story: Metformin, B12, and Women on Intrarosa

This is the interaction framework no other article on this topic has laid out explicitly. Three commonly co-prescribed agents appear in the same woman with some regularity: Intrarosa for GSM, metformin for PCOS or type 2 diabetes, and a B12 supplement either self-selected or clinician-recommended. Understanding which pair actually interacts matters for clinical decision-making.

Pair 1: Intrarosa + Vitamin B12. No interaction. Different routes (vaginal vs. Gastrointestinal), different metabolic pathways, no shared enzymes or transporters.

Pair 2: Metformin + Vitamin B12. Clinically significant. Metformin reduces ileal uptake of the B12-intrinsic factor complex by competing with calcium-dependent membrane receptors in the terminal ileum. A 2010 DPPOS analysis published in the Archives of Internal Medicine found that 29% of metformin users had borderline-low or deficient B12 levels after 5 years of treatment versus 17% of placebo users.

Pair 3: Intrarosa + Metformin. No established pharmacokinetic interaction. Prasterone is locally metabolized; it does not affect metformin renal clearance or hepatic metabolism.

The takeaway: if you take all three, B12 supplementation makes clinical sense, not because of Intrarosa, but because of metformin.

How Metformin Depletes B12

Metformin blocks the calcium-dependent ileal transporter that allows the B12-intrinsic factor complex to bind to enterocyte receptors for absorption. This effect is dose-dependent and duration-dependent. Women on doses of 2,000 mg/day or higher for more than 3 years face the greatest depletion risk. Because neurological symptoms from B12 deficiency can mimic diabetic neuropathy, the deficiency often goes unrecognized.

PCOS, Metformin, and the Intrarosa User

Women with PCOS are disproportionately represented among Intrarosa users who also take metformin. Many women with PCOS develop GSM-like atrophic symptoms earlier than their peers due to intermittent hypo-estrogenic states or extended amenorrhea. PCOS is present in approximately 8-13% of reproductive-age women and remains the leading cause of anovulatory infertility. Metformin is a first-line insulin sensitizer in this population. A woman with PCOS who transitions into perimenopause or develops POI may find herself on both metformin and Intrarosa, making B12 monitoring particularly important.

Life-Stage Guide to Intrarosa and B12

Women's B12 needs and Intrarosa eligibility shift significantly across life stages. Here is how to think about each.

Reproductive Years (Ages 18-40)

Intrarosa is not approved for premenopausal women and is not typically prescribed during the reproductive years. B12 requirements are 2.4 mcg/day. Women in this group who take metformin for PCOS should have serum B12 checked annually. Supplementation with 500-1,000 mcg/day of cyanocobalamin or methylcobalamin is a reasonable preventive step.

Perimenopause (Ages 40-51)

GSM symptoms can begin in perimenopause as estrogen fluctuates. Intrarosa is not FDA-approved for perimenopausal women, though some clinicians prescribe it off-label. B12 absorption starts to decline after age 50 due to reduced gastric acid. Women in their mid-40s on long-term metformin should already be monitoring B12.

Postmenopause (Ages 51 and Beyond)

This is Intrarosa's approved population. Gastric atrophy becomes more common, compounding B12 absorption difficulty. The American Gastroenterological Association recommends that adults over 50 obtain B12 from fortified foods or supplements rather than relying solely on food-bound sources. If you are postmenopausal, using Intrarosa, and on metformin, a baseline serum B12 level and annual recheck is straightforward practice.

Premature Ovarian Insufficiency (POI)

Women with POI who receive Intrarosa off-label are typically younger, but their metabolic risk profile often includes insulin resistance. If metformin is also part of their regimen, the B12 depletion concern applies identically to reproductive-age women with POI.

Pregnancy and Lactation Safety

Intrarosa is contraindicated in pregnancy. Prasterone is an androgen precursor. Exposure in pregnancy carries theoretical risk of fetal virilization. The FDA label carries an explicit contraindication for use during pregnancy. If you are pregnant or think you might be pregnant, do not use Intrarosa.

Intrarosa is approved for postmenopausal women, so pregnancy is not expected in the typical user. Still, women with POI who still have rare, unpredictable cycles, or perimenopausal women using Intrarosa off-label, should use reliable contraception. The FDA drug label does not assign a formal letter category (the old A/B/C/D/X system was retired in 2015) but states clearly that prasterone should not be used during pregnancy.

Lactation. No human data exist on prasterone transfer into breast milk. Because DHEA is a steroid precursor that may convert to sex hormones, avoiding Intrarosa during breastfeeding is the cautious recommendation. A clinician should weigh the severity of GSM symptoms against the lack of safety data before prescribing to a breastfeeding woman.

Vitamin B12 in pregnancy and lactation. B12 is safe and necessary during pregnancy and breastfeeding. Requirements increase to 2.6 mcg/day in pregnancy and 2.8 mcg/day during lactation. Standard prenatal vitamins typically provide 6-12 mcg. High-dose B12 supplementation (up to 1,000 mcg) has not been associated with fetal harm. Women who are vegan, vegetarian, or on metformin during pregnancy face particular risk of deficiency and should be monitored closely.

Pharmacokinetics: Why Vaginal Delivery Changes the Calculus

Oral DHEA supplements produce significant first-pass hepatic metabolism, with roughly 50% converted before reaching systemic circulation. Intrarosa's vaginal route bypasses this entirely. Prasterone absorbs through vaginal mucosa and converts locally within epithelial cells to estrogens and androgens.

A pharmacokinetic sub-study in the REJOICE trial confirmed that serum DHEA-S, estradiol, and testosterone levels remained within normal postmenopausal reference ranges after 12 weeks of nightly use. This modest systemic exposure is one reason clinicians believe Intrarosa poses a different risk profile from oral DHEA or systemic estrogen, and why it does not create meaningful drug interactions the way oral agents often do.

Because B12 metabolism does not involve vaginal tissue, estrogen receptors, androgen receptors, or CYP450 isoforms activated by prasterone, no mechanistic basis for an Intrarosa-B12 interaction exists.

Monitoring Recommendations

Even without a direct Intrarosa-B12 interaction, certain women on Intrarosa warrant B12 monitoring for independent reasons.

If You Are on Metformin

• Baseline serum B12 before starting metformin or at your next annual visit
• Annual recheck while on metformin doses above 1,000 mg/day
• Target serum B12 above 300 pg/mL (some labs flag deficiency at <200 pg/mL, but neurological symptoms appear at levels between 200-300 pg/mL in many women)
• Supplemental B12 of 500-1,000 mcg/day is a reasonable preventive dose; sublingual or intramuscular routes offer better absorption if gastric issues are present

If You Are Over 50

• Consider routine B12 screening at your annual well-woman visit
• Rely on crystalline B12 (supplements or fortified foods) rather than food-bound sources, as gastric acid production declines with age

If You Are Vegan or Vegetarian

• B12 deficiency risk is high regardless of Intrarosa or metformin use
• 1,000 mcg/day of cyanocobalamin or methylcobalamin is a standard supplemental dose for this group, as confirmed by the NIH ODS position on dietary supplements

Other Drugs That Do Interact With Intrarosa

Vitamin B12 is safe. Other agents deserve more caution when you are using Intrarosa.

Tamoxifen and Aromatase Inhibitors

Prasterone converts locally to estradiol. Theoretically, this local estrogen production could counteract tamoxifen or aromatase inhibitor therapy in breast cancer survivors. Evidence is limited to theoretical concern, but most oncologists prefer to avoid Intrarosa in women actively on anti-estrogen therapy. The NAMS 2023 position statement advises caution and shared decision-making in this population.

Systemic Sex Hormones

No clinical trial data show a significant interaction between Intrarosa and concurrent systemic estrogen or progesterone therapy. Because prasterone adds local androgen and estrogen activity, combined use could theoretically increase overall hormonal exposure, though serum levels in the REJOICE trial remained within postmenopausal ranges even at the 6.5 mg dose.

Warfarin

Sex hormones can affect clotting factors and INR. Women on warfarin starting Intrarosa should have INR rechecked within 2-4 weeks of initiation, though the local delivery route makes a clinically significant interaction less likely than with oral estrogens.

Who This Is Right For (and Not Right For)

Good Candidates for Intrarosa

• Postmenopausal women with confirmed GSM causing moderate-to-severe dyspareunia or vaginal dryness
• Women who cannot or prefer not to use systemic estrogen
• Women with a personal history of hormone-receptor-negative breast cancer (discuss with your oncologist)
• Women on metformin who can supplement B12 appropriately

Not the Right Fit

• Pregnant women (contraindicated)
• Breastfeeding women (insufficient data; avoid)
• Women on tamoxifen or aromatase inhibitors (theoretical concern; discuss with oncologist)
• Women with unexplained vaginal bleeding (rule out endometrial pathology first)
• Premenopausal women who are ovulating normally (GSM is unlikely in this group)

What to Tell Your Clinician

When you bring up B12 with your prescriber, frame the conversation around your full medication list, not just Intrarosa. Specifically, mention:

1. Whether you take metformin, even intermittently
2. Your dietary pattern (vegan, vegetarian, or omnivore)
3. Any history of gastrointestinal surgery or autoimmune conditions affecting the stomach
4. Your current B12 supplement dose if you already take one

A 2019 Annals of Internal Medicine review on B12 deficiency in adults confirmed that symptoms, including fatigue, tingling, and cognitive fog, are nonspecific and overlap significantly with menopause symptoms. Getting a serum B12 measured once during your menopausal transition is simple and inexpensive, and it closes a diagnostic gap that many clinicians miss.

The Evidence Gap

Women have historically been under-represented in pharmacokinetic interaction studies. The REJOICE trial was conducted entirely in postmenopausal women, which is appropriate for Intrarosa's indication, but it did not assess supplement co-administration in any systematic way. No published trial has examined the combination of prasterone, metformin, and B12 simultaneously. The conclusion that no interaction exists is based on mechanistic reasoning (different pathways, local vs. Systemic delivery) rather than a dedicated interaction study. This is an honest gap. For women who want to be certain, a straightforward serum B12 measurement before and after any medication change is the most direct answer available.